Valeant Pharmaceuticals International Revenue and Competitors
Estimated Revenue & Valuation
- Valeant Pharmaceuticals International's estimated annual revenue is currently $460.5M per year.
- Valeant Pharmaceuticals International's estimated revenue per employee is $321,600
- Valeant Pharmaceuticals International's total funding is $1.2B.
Employee Data
- Valeant Pharmaceuticals International has 1432 Employees.
- Valeant Pharmaceuticals International grew their employee count by 1% last year.
Valeant Pharmaceuticals International's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP/President, International | Reveal Email/Phone |
2 | EVP /General Counsel | Reveal Email/Phone |
3 | SVP Diversified Products | Reveal Email/Phone |
4 | SVP Manfacturing/Supply Chain | Reveal Email/Phone |
5 | Director Process Excellence | Reveal Email/Phone |
6 | Quality Compliance Director EMEA | Reveal Email/Phone |
7 | Director, Corporate Audit Services | Reveal Email/Phone |
8 | Associate Director, Epilepsy Marketing | Reveal Email/Phone |
9 | Senior Director Technical Operations | Reveal Email/Phone |
10 | HR& Administration Director | Reveal Email/Phone |
Valeant Pharmaceuticals International Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Valeant Pharmaceuticals International?
Valeant Pharmaceuticals International (NYSE: VRX) is a global, research-based, specialty pharmaceutical company that discovers, develops, manufactures and markets pharmaceutical products, primarily in the areas of neurology, dermatology and infectious disease. Valeant has made rapid strides under a new management team that laid out a strategic vision with a renewed focus on its specialty pharmaceuticals business, and has implemented major changes in the areas of product management, business development, research and development, corporate governance and supply chain operations.
keywords:N/A
$1.2B
Total Funding
1432
Number of Employees
$460.5M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Valeant Pharmaceuticals International News
... Astellas Pharma Inc. (Japan), Sanofi S.A. (France), Regeneron Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals International,.
In early 2015, he made an ill-fated bet on Valeant Pharmaceuticals International, which resulted in two years of double-digit portfolio...
Novartis; Allergan; Valeant Pharmaceuticals; Santen Pharmaceutical; Lupin Pharmaceuticals; Apotex; Akorn. Customization of the Report: This report can be...
Other Companies in Bridgewater
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $300M | 1477 | 6% | N/A |
#2 | $276.2M | 1805 | -2% | $68M |
#3 | $700.7M | 2043 | N/A | N/A |
#4 | $1325.3M | 5259 | N/A | N/A |
#5 | $2070M | 5360 | 8% | $854M |